Affibody and Biotest sign research licensing deal


Affibody will receive up-front and milestone payments in addition to royalties

Swedish biotech company Affibody has signed a research licensing agreement with Biotest of Germany concerning Affibody's proprietary Albumod platform, which enhances the efficacy of biopharmaceuticals by extending their circulatory half-life, and will be used with compounds from Biotest’s portfolio of proprietary molecules.

The Albumod technology allows for less frequent dosing and lower peak concentrations in blood with a decreased risk for adverse events. In addition to these patient safety benefits, the overall treatment costs are reduced.

Affibody will receive up-front and milestone payments from Biotest as well as royalties on sales for licensing of the Albumod platform. No financial details have been disclosed.

Sign up for your free email newsletter

Affibody’s CEO, David Bejker, said: 'Biotest with its vast experience in development of protein-based drugs is an ideal partner for our Albumod platform and we are very pleased to announce this agreement. This announcement further illustrates that our licence-driven business model can continue to deliver new collaborations.'